Drug Trial Radar · NCT05843916
Switch Over Study of Biosimilar Agalsidase Beta for Fabry Disease
Last checked: Nov 20, 2026Latest source record: Feb 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
20
Actual
Start
Dec 13, 2022
Primary completion
Sep 19, 2024
Study completion Mar 31, 2025
Sponsor
- Lead sponsor
- Bio Sidus SAIndustry
- Sponsor type
- Industry
- Collaborators
- Amsterdam UMC; IQVIA Pty Ltd; IQVIA RDS Inc.
- First posted
- May 6, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 16 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
BIO-AGA-Fase III-001 is a Phase III, prospective, multicenter, open-label, single-group, baseline-controlled, switch over clinical trial to evaluate the efficacy and safety of AGA BETA BS in patients with FD already treated and previously stabilized with Fabrazyme®.
Conditions
- Fabry Disease
Interventions
Recombinant human alpha galactosidase A (agalsidase beta)Drug
All participants will receive 2 doses of Fabrazyme® with approximately 14 days between them. The dose will be 1 mg/kg of body mass every 2 weeks
Recombinant human alpha-galactosidase A (agalsidase beta)Drug
All participants will receive AGA BETA BS for 54 weeks. The dose will be 1 mg/kg of body mass every 2 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Lyso Gb3 Serum LevelsTime frame: Baseline (after 5 week lead-in period on Fabrazyme®) and 26 weeks (after the switch to AGA BETA BS)
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Instituto de Investigaciones Clínicas Quilmes
Buenos Aires, Argentina
Clínica Universitaria Reina Fabiola
Córdoba, Argentina
Centro Oncológico Riojano Integral
La Rioja, Argentina
Instituto de Nefrología Pergamino S.R.L
Pergamino, Buenos Aires, Argentina
Centro Médico Santa María de la Salud
San Isidro, Buenos Aires, Argentina
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.